Your browser doesn't support javascript.
loading
Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells.
Sun, Fengqiang; Yu, Xiaomei; Ju, Ruixue; Wang, Zhanzhao; Wang, Yuhui.
Afiliación
  • Sun F; Department of Clinical Laboratory, Weifang People's Hospital, Weifang, 261000, Shandong, China.
  • Yu X; Department of Obstetrics, Weifang People's Hospital, Weifang, 261000, Shandong, China.
  • Ju R; Department of Clinical Laboratory, Weifang People's Hospital, Weifang, 261000, Shandong, China.
  • Wang Z; Department of Clinical Laboratory, Weifang People's Hospital, Weifang, 261000, Shandong, China.
  • Wang Y; Department of Clinical Laboratory, Weifang People's Hospital, Weifang, 261000, Shandong, China. Wangyuhui_wfrm@163.com.
Cancer Cell Int ; 22(1): 50, 2022 Jan 31.
Article en En | MEDLINE | ID: mdl-35101032
BACKGROUND: Gastric cancer (GC) has a poor prognosis and limited therapeutic options. As a new promising cancer therapeutic approach, chimeric antigen receptor (CAR)-T cells represent a potential GC treatment. We investigated the antitumor activity of CAR-T cells target-B7H3 in GC. METHODS: In our study, expression of B7H3 was examined in GC tissues and explored the tumoricidal potential of B7H3-targeting CAR-T cells in GC. B7H3-directed CAR-T cells with a humanized antigen-recognizing domain was generated. The anti-tumor effects of this CAR-T cell were finally investigated in vitro and in vivo. RESULTS: Our results show that B7H3-directed CAR-T cells efficiently killed GC tumor cells. In addition, we found that B7H3 is correlated with tumor cell stemness, and anti-B7H3 CAR-T can simultaneously target stem cell-like GC cells to improve the treatment outcome. CONCLUSIONS: Our study indicates that B7H3 is an attractive target for GC therapy, and B7H3 has high potential for clinical application.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancer Cell Int Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancer Cell Int Año: 2022 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido